BCI & Neuroscience
Brain-computer interfaces, neural decoding, neuroprosthetics, invasive and non-invasive BCI clinical trials
Non-Invasive BCI: Neural Signal Decoding and Flexible Bioelectronics
Deep learning for neural decoding + flexible bioelectronics integration for non-invasive BCI
BCI in Neuroprosthetics & Neurorehabilitation
Active research topic on BCI for motor recovery, speech restoration, neurological disorders
BraIn-to-Text (BIT): Neural Speech Decoding Framework
BraIn-to-Text (BIT) framework. Neural activity to sentences via single differentiable network. 10% word error rate (down from 24.69%). Contrastive learning cross-modal alignment with audio LLMs.
A Review of Brain-Computer Interface Technologies: Signal Acquisition Methods and Interaction Paradigms
Comprehensive cross-level taxonomy linking BCI paradigms (Motor Imagery, P300, SSVEP, hybrid, auditory/olfactory/tactile) to signal acquisition techniques across three invasiveness tiers
Application and Future Directions of Brain-Computer Interfaces in Neurological Disorders: Technological Advances, Clinical Practices, and Challenges
Clinical-focused systematic review synthesizing BCI applications across motor, speech, cognitive, and sensory deficits with AI/VR integration frameworks and personalized digital prescription pathways
A Comprehensive Review of AI-Based Brain-Computer Interface with Prefrontal Cortex and Sensory-Motor Rhythms Systemization for Rehabilitation
Systematic comparative review of AI classification techniques for EEG-based motor imagery and eye-state BCIs, benchmarking signal processing pipelines across public datasets with focus on rehabilitation applicability
Stabilizing brain-computer interfaces through alignment of latent dynamics (NoMAD)
NoMAD stabilizes BCI decoding across weeks-to-months without supervised recalibration via unsupervised manifold alignment.
Long-term independent use of an intracortical brain-computer interface for speech and cursor control
A man with ALS and severe dysarthria used a multimodal intracortical BCI (speech + cursor) for >3,800 hours at home over ~2 years with no researchers present — 183,060 sentences / 1,960,163 words at avg 56 wpm, 92% of sentences decoded at least mostly correctly. Strongest evidence yet for durable, unsupervised at-home speech-BCI use.
Surgical Planning Pipeline for Human Implantable Brain-Computer Interfaces
First systematic surgical planning pipeline for implantable BCI — pre-op imaging + vasculature mapping + target site selection + trajectory optimization. Addresses workflow standardization as BCI moves to multi-site clinical deployment
Multimodal Brain-Computer Interfaces: AI-Powered Decoding Methodologies
Comprehensive review of AI-powered multimodal BCI decoding — unifies cross-modality mapping, sequential modeling, and fusion. Identifies multimodal Transformers as next-gen decoder architecture
Neuralink PRIME Study: International Expansion and Clinical Results
~20 patients implanted; thought-controlled computing; UK/UAE trial expansion
Synchron Stentrode: Primary Endpoint Met in Feasibility Trial
12-month safety+efficacy data, 6 patients. First FDA-approved permanently implanted BCI. $200M Series D for pivotal trials 2026.
Stanford: Decoding Inner Speech from Motor Cortex
Decoded private inner monologue from motor cortex microelectrode arrays. 4 patients with severe paralysis. Inner speech patterns similar but smaller version of attempted speech patterns.
University of Michigan implants first-in-human Paradromics Connexus wireless BCI (Connect-One EFS)
First-in-human implant of the Paradromics Connexus wireless intracortical BCI (421 microelectrodes; chest transceiver; transcutaneous link) at University of Michigan on a woman with motor neuron disease, under the FDA-approved Connect-One EFS. >200 bits/sec info transfer in preclinical models; speech-first design.
Synchron preps 2026 Stentrode pivotal trial — path to first FDA PMA of an implantable BCI
Synchron preparing a 2026 pivotal trial of the endovascular Stentrode — the study it must clear to file the first-ever FDA PMA for a permanently implanted BCI. Builds on COMMAND (6 patients, no device-related serious adverse events over 12 months, NCT05035823) and a $200M Series D (Nov 6, 2025).
Neuralink 2026: VOICE speech trial, Blindsight vision program, ~24 patients, high-volume rollout
By May 2026 Neuralink had implanted >=24 patients. New programs beyond cursor/typing: VOICE (speech restoration, FDA Breakthrough, 2 patients), CONVOY (robotic-arm control), Blindsight (visual-cortex vision restoration, FDA Breakthrough 2024, first trials 2026 with Cleveland Clinic Abu Dhabi). $650M raise (~$9B valuation); planned high-volume automated-surgery rollout.
Paradromics Cleared to Start Connexus Long-Term Clinical Speech Trial
FDA approves Paradromics first long-term clinical trial of Connexus speech BCI. Connexus claims >200 bps info transfer rate — 20× Neuralink N1, orders of magnitude beyond Synchron Stentrode